Durata has a market cap of around $280 million. Tetraphase Pharma has a market cap of around $360 million. Dalbavancin will probably be approved this year. When comparing the 2 companies, it doesn't make much sense to me why Tetraphase Pharma has the larger market cap. Seems to me, it should be the other way around.
Silver..... I posted the same question here many moons ago and was told by one of our physician posters that DRTX is basically a one drug, one product company, while TTPH, although not as far along in the clinical trial process, has a very deep and varied pipeline. Interesting. Own both large.